Arcturus Therapeutics Holdings Inc. (ARCT)
ARCT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1768224/000119312526088391/0001193125-26-088391-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ARCT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2013 |
| SEC CIK | 0001768224 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $82.0M |
| Net income | -$65.8M |
| Operating income | -$76.3M |
| Net margin | -80.2% |
| Operating margin | -93.0% |
| Revenue growth | -46.1% |
| Cash | $230.9M |
| Total assets | $271.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $184.8M cash; operating cash flow -$15.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 28,822,514 (2026-11-03); 28,412,537 a year earlier; 26,723,332 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2025-12-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Diego, California, United States | PCAOB Form AP 2026-03-12 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $18.3M | -$7.4M | -$6.9M | $184.8M | No debt tags | $30.5M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $3.0M | -$23.8M | -$19.9M | $191.5M | No debt tags | $29.4M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $2.1M | -$27.0M | -$19.4M | $211.4M | No debt tags | $54.7M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $7.2M | -$29.1M | -$16.2M | $230.9M | No debt tags | $82.0M | 10-K 2026-03-03 |
| Q3 2025 2025-09-30 | $17.2M | -$13.4M | -$17.2M | $180.4M | No debt tags | $97.6M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $28.3M | -$9.2M | -$5.8M | $196.5M | No debt tags | $122.1M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $29.4M | -$14.1M | -$35.1M | $216.9M | $15.0M | $143.7M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $22.8M | -$30.0M | -$284K | $237.0M | No debt tags | $152.3M | 10-K 2026-03-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2025-12-30 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 418 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -19.2% |
| 1 month | -30.5% |
| 3 months | +6.4% |
| Year to date | +36.4% |
| 1 year | +7.6% |
| From 52-week high | -50.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FTH | Faeth Therapeutics Inc. | $9.28 | -7.48% | $239.8M |
| BIOA | BioAge Labs Inc. | $5.22 | -5.95% | $239.9M |
| RCKT | Rocket Pharmaceuticals Inc. | $2.16 | -6.09% | $241.2M |
| CAMP | CAMP4 Therapeutics Corporation | $3.86 | +1.58% | $242.2M |
| LFCR | Lifecore Biomedical Inc. | $6.42 | -0.08% | $243.2M |
| AMRN | Amarin Corporation plc | $11.31 | -0.62% | $233.4M |
| QTTB | Q32 Bio Inc. | $8.29 | -4.82% | $248.1M |
| VNDA | Vanda Pharmaceuticals Inc. | $3.81 | -4.51% | $230.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier